Related Experiment Video

Updated: Jun 6, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Novel alternatives for anti-angiogenetic therapy and therapeutic angiogenesis

M Mazzone1

  • 1Vesalius Research Center, VIB--KULeuven--Campus Gasthuisberg, Herestraat 49, Box 912--B-3000 Leuven.

Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie
|November 12, 2010
PubMed

Insights

Novel strategies targeting oxygen sensors like PHD2 and PHD1 offer new hope for treating cancer and ischemic diseases. These approaches aim to normalize tumor vasculature and enhance hypoxia tolerance, addressing limitations of current therapies.

Area of Science:

  • Vascular biology
  • Oncology
  • Ischemic disease research

Background:

  • Anti-angiogenic therapy and therapeutic angiogenesis have limitations in treating cancer and ischemic diseases, respectively.
  • Current strategies often fail in clinical trials, necessitating novel therapeutic approaches.
  • Understanding oxygen sensing mechanisms in vasculature is crucial for developing effective treatments.

Purpose of the Study:

  • To identify novel targets for normalizing tumor vasculature and reducing cancer hypoxia.
  • To evaluate anti-placental growth factor (anti-P1GF) as a safe and effective cancer therapy.
  • To explore hypoxia tolerance via PHD1 inhibition as an alternative to therapeutic angiogenesis.

Main Methods:

  • Investigated the role of the PHD2 oxygen sensor in regulating tumor vasculature and oxygen supply.
  • Assessed the efficacy and safety of anti-P1GF in cancer models.
  • Examined the potential of inhibiting the PHD1 oxygen sensor to induce hypoxia tolerance.

Main Results:

  • PHD2 was identified as a target for normalizing tumor vasculature, reducing hypoxia, and preventing cancer cell spread.
  • Anti-P1GF demonstrated efficacy and safety without excessive pruning of pathological or normal vasculature.
  • PHD1 inhibition showed potential as an alternative strategy to therapeutic angiogenesis for ischemic disorders.

Conclusions:

  • Targeting oxygen sensors provides new therapeutic avenues for cancer and ischemic diseases.
  • PHD2 normalization of tumor vasculature and anti-P1GF offer promising cancer treatment strategies.
  • PHD1 inhibition presents a novel approach for managing ischemic conditions.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...